Nanoparticles with controlled size and high homogeneityParticle size can be controlled from 40 nm to 200 nm with a polydispersity index (PDI) less than 0.2；
Results with high reproducibilityPrecise flow rate control with error ≤2%. Automatic switching between products and pre/post-waste, which reduce batch-to-batch variation.
Operation with smart controlMicrofluidic chip performance is constantly monitored to avoid possible channel congestion or leakage. Valuable samples can be saved in any undesirable situations. Products and pre/post-waste are automatically switched.
Lower running cost The microfluidic mixing chip is made of COC, which is highly stable against most organic and inorganic solvents. Breaking pressure of microfluidic chip is more than 50 Bar (5 MPa) , which is strong enough to tolerate much high flow rate.Chip can be cleaned and re-used more than 50 times.
Use with ease and high efficiencySmart LNP Generator is equipped with touch screen control, so no external computer is needed. 256 different experiment protocols can be saved and loaded with single touch. Experiments can be performed within 30 seconds after powering on. It takes 3-60 seconds for a single run, which means hundreds of formulations can be sceended in a single day.
In the process of Lipid Nanoparticles (LNP) assembly, uniform mixing of ethanol phase (containing ionizable lipids) and aqueous phase (containing bio-molecules such as RNA and DNA) is the key step. By leveraging the cutting-edge microfluidic technology, Smart LNP Generator S1 is capable of generating homogeneous nanoparticles with controlled size and high reproducibility. The very low reagent consumption, and easy of use, make the Smart LNP Generator the ideal platform for early-stage drug development.
Other advantages:
Dead volume is minimized. Total sample volume can be reduced to 0.6 ml.
Built-in pressure and position sensors for precise control of sample flow rate
Advanced flow acceleration algorithm reduces 50% of flow rate ramping time, significantly reducing pre-waste；
Dual-channel flow control, flow rate ratio can be set from 10:1 to 1:10
Microfluidic mixing chip for LNP-B1
LNP-B1 is a micromixer with classical staggered herringbone structure. It is made by pure COC. which is highly stable against most organic and inorganic solvents. Chip can be cleaned and reused more than 50 times. Breaking pressure of microfluidic chip is more than 50 Bar (5 MPa). LNP- B1 has extremely low dead volume, so the total sample volume can be reduced to 0.6 ml.
LNP-B1 parameter:
Chip structure
staggered herringbone micromixer
material
Pure COC
LNP particle size:
40~200 nm;
Total flow rate range:
0.04 ~ 36 mL/min (flow rate ratio: 1:3);
laminar mixing time
< 3 ms;
Breaking pressure
> 50 Bar (5 MPa) .
laminar mixing time < 3 ms;
Chip is made of pure COC with extraordinary strength;
The microfluidic mixing chip is made of COC, which is highly stable against most organic and inorganic solvents. Chip can be cleaned and reused more than 50 times. Breaking pressure of microfluidic chip is more than 50 Bar (5 MPa) .
Collected experimental data:
Figure 1: Particle Size Distribution of unloaded LNP after dilution. (Z-average size=50.77; PDI=0.045) .
Figure 2: Particle Size Distribution of LNP-mRNA after dilution.(Z-average size=65.65; PDI=0.058).
Figure 3: Final Product of LNP Encapsulating SARS-CoV-2 NTD-RBD mRNA.
Figure 4:Cryo-EM of mRNA-LNP.
Figure 5: Images of EGFP-LNP transfected HEK-293T Cells (16 hours after transfection).
Figure 6: Flow cytometry analysis of cell transfected with LNP-(EGFP)mRNA, more than 80% cells express EGFP.
Figure 7: In vivo imaging of mouse transfected with LNP-(luciferase)mRNA.
References Published by the Customer:
[1] Y. Shi et al., ‘Structural and biochemical characteristics of mRNA nanoparticles determine anti–SARS-CoV-2 humoral and cellular immune responses’, Sci. Adv., vol. 8, no. 47, p. eabo1827, Nov. 2022, doi: 10.1126/sciadv.abo1827.
[2] L. Ai et al., ‘Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2’, Cell Discov., vol. 9, no. 1, p. 9, Jan. 2023, doi: 10.1038/s41421-022-00517-9.
[3] N. Zhang et al., ‘Multi-valent mRNA vaccines against monkeypox enveloped or mature viron surface antigens demonstrate robust immune response and neutralizing activity’, Sci. China Life Sci., vol. 66, no. 10, pp. 2329–2341, Oct. 2023, doi: 10.1007/s11427-023-2378-x.
[4] X. Tang et al., ‘Simultaneous dendritic cells targeting and effective endosomal escape enhance sialic acid-modified mRNA vaccine efficacy and reduce side effects’, J. Controlled Release, vol. 364, pp. 529–545, Dec. 2023, doi: 10.1016/j.jconrel.2023.11.008.
